<DOC>
	<DOCNO>NCT01031173</DOCNO>
	<brief_summary>The study evaluate safety efficacy Replagal® ( agalsidase alfa ) dose 0.2 mg/kg infuse intravenously ( IV ) 40 minute , every week . The study monitor course disease male females Fabry disease naive treatment previously treat agalsidase beta ( Fabrazyme® ) .</brief_summary>
	<brief_title>Treatment Protocol Replagal Patients With Fabry Disease</brief_title>
	<detailed_description>This study evaluate safety efficacy Replagal patient Fabry disease either naive treatment , previously treat agalsidase beta , previously receive Replagal . Patients diagnose Fabry disease previously receive treatment , receive agalsidase beta , previously receive Replagal eligible enroll study receive Replagal dose 0.2 mg/kg body weight administer IV infusion 40 minute every week . This study conduct United States . Study visit occur 3 phase : - Screening/Baseline Phase : A Screening/Baseline period ( Day -30 Day -1 ) determine eligibility obtain baseline measurement . Patients previously receive agalsidase beta test presence anti-agalsidase beta antibody . - Treatment Phase : A 12-month treatment phase patient receive Replagal administer IV every week . Clinical assessment occur Months 1 , 3 , 6 , 9 , 12 . The study may extend continue give patient access treatment . - End-of-Study Phase : An end-of-study contact either office visit follow-up telephone call occur one month last infusion .</detailed_description>
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>1 . Confirmed diagnosis Fabry disease . 2 . Patient willing able provide write informed consent , assent applicable . 3 . Females childbearing potential must agree use method birth control throughout study least 30 day final infusion . The method contraception must consider adequate appropriate opinion investigator . 1 . Hypersensitivity Replagal , active substance , excipients . 2 . The patient pregnant breast feeding . 3 . Concomitant use agalsidase beta ( Fabrazyme ) . 4 . Has receive treatment investigation drug device within 30 day prior study entry . 5 . Otherwise unsuitable study , opinion Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>α galactosidase A</keyword>
	<keyword>glycosphingolipid storage disorder</keyword>
	<keyword>agalsidase alfa</keyword>
	<keyword>enzyme replacement therapy</keyword>
	<keyword>Replagal</keyword>
	<keyword>agalsidase beta</keyword>
	<keyword>Fabrazyme</keyword>
</DOC>